7,098 Shares in Medtronic PLC $MDT Acquired by A4 Wealth Advisors LLC

A4 Wealth Advisors LLC bought a new stake in shares of Medtronic PLC (NYSE:MDT) in the third quarter, HoldingsChannel reports. The institutional investor bought 7,098 shares of the medical technology company’s stock, valued at approximately $676,000.

Other institutional investors have also added to or reduced their stakes in the company. Delos Wealth Advisors LLC bought a new stake in Medtronic during the second quarter valued at about $27,000. Corundum Trust Company INC purchased a new position in shares of Medtronic during the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. bought a new position in shares of Medtronic during the 3rd quarter valued at approximately $29,000. Steigerwald Gordon & Koch Inc. purchased a new stake in Medtronic in the 3rd quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC purchased a new stake in Medtronic in the 3rd quarter worth approximately $34,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Trading Up 1.9%

Shares of Medtronic stock opened at $102.96 on Monday. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The business has a 50-day moving average price of $99.60 and a 200-day moving average price of $95.73. The firm has a market cap of $131.99 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 2.71 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the company an “outperform” rating in a report on Wednesday, November 19th. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, Royal Bank Of Canada boosted their price objective on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Fifteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).